p53 elevation in relation to levels and cytotoxicity of mono- and bifunctional melphalan-DNA adducts

Molecular Pharmacology

Volumn 66, Issue 5, 2004, Pages 1301-1309

  Gould, Katherine A ^a   Nixon, Cally ^a   Tilby, Michael J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; HYDROXYMELPHALAN; MELPHALAN; PROTEIN P53; UNCLASSIFIED DRUG;

ALKALINITY; ALKYLATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA DETERMINATION; DNA STRAND; ELUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FOLDING; QUANTITATIVE ANALYSIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL PROLIFERATION; DNA; DNA ADDUCTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROGEN-ION CONCENTRATION; MELPHALAN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 6944253481     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.000596     Document Type: Article

References (40)

1. Abbas T, Olivier M, Lopez J, Houser S, Xiao G, Kumar GS, Tomasz M, and Bargonetti J (2002) Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem 277:40513-40519.
2. Achanta G, Pelicano H, Feng L, Plunkett W, and Huang P (2001) Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 61:8723-8729.
3. Begleiter A, Lam H-YP, Grover J, Froese E, and Goldenberg GJ (1979) Evidence for active transport of melphalan by two amino acid carriers in L5178Y lymphoblasts in vitro. Cancer Res 39:353-359.
4. Ducore JM, Erickson LC, Zwelling LA, Laurent G, and Kohn KW (1982) Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum (II) and L-phenylalanine mustard. Cancer Res 42:897-902.
5. Evans DL, Tilby MJ, and Dive C (1994) Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res 54:1596-1603.
6. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW, and O'Connor PM (1994) P53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824-5830.
7. Frank AJ and Tilby MJ (2003) Quantification of DNA adducts in individual cells by immunofluorescence: effects of variation in DNA conformation. Exp Cell Res 283:127-134.
8. Gottifredi V, Shieh S-Y, Taya Y, and Prives C (2001) p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc Natl Acad Sci USA 98:1036-1041.
9. Hansson J, Lewensohn R, Ringborg U, and Nilsson B (1987) Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 47:2631-2637.
10. Houser S, Koshlatyi S, Lu T, Gopen T, and Bargonetti J (2001) Camptothecin and zeocin can increase p53 levels during all cell cycle stages. Biochem Biophys Res Commun 289:998-1009.
11. 1 arrest. Proc Natl Acad Sci USA 93:4827-4832.
12. Iliakis G, Wang Y, Guan J, and Wang H (2003) DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 22:5834-5847.
13. Kastan MB, Onyekewere O, Sidransky D, Vogelstein B, and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
14. Kohn KW, Ewig RAG, Erickson LC, and Zwelling LA (1981) Measurement of strand breaks and cross links by alkaline elution, in DNA Repair: A Laboratory Manual of Research Procedures (Hanawalt PC and Friedberg EC eds) pp 379-401, Marcel Dekker, New York.
15. Lowe SW, Ruley HE, Jacks T, and Housman DE (1993) P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
16. Mattes WB, Lee C-S, Laval J, and O'Connor TR (1996) Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glysosylases. Carcinogenesis 17:643-648.
17. McCartney H, Martin AM, Middleton PG, and Tilby MJ (2001) Antibody recognition of melphalan adducts characterized using immobilized DNA: enhanced alkylation of G-rich regions in cells compared to in vitro. Chem Res Toxicol 14:71-81.
18. Melton RG, Knox R, and Connors TA (1996) Antibody-directed enzyme prodrug therapy (ADEPT). Drugs Future 21:167-181.
19. Meyer KM, Hess SM, Tlsty TD, and Leadon SA (1999) Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light. Oncogene 18:5795-5805.
20. Millar BC, Tilby MJ, Ormerod MG, Payne AWR, Jinks S, and Loverock PS (1986) Comparative studies of total cross-linking, cell survival and cell cycle perturbations in Chinese hamster cells treated with alkylating agents in vitro. Biochem Pharmacol 35:1163-1169.
21. Monks NR, Blakey DC, Curtin NJ, East SJ, Heuze A, and Newell DR (2001) Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. Br J Cancer 85:764-771.
22. Monks NR, Blakey DC, East SJ, Dowell RI, Calvete JA, Curtin NJ, Arris CE, and Newell DR (2002) DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767. Eur J Cancer 38:1543-1552.
23. Nelson WG and Kastan MB (1994) DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815-1823.
24. Osborne MR and Lawley PD (1992) The reaction of melphalan with deoxyguanosine and deoxyguanylic acid. Chem Biol Interact 84:189-198.
25. Osborne MR and Lawley PD (1993) Alkylation of DNA by melphalan with special reference to adenine derivatives and adenine-guanine cross-linking. Chem Biol Interact 89:49-60.
26. Osborne MR, Lawley PD, Crofton-Sleigh C, and Warren W (1995a) Products from alkylation of DNA in cells by melphalan: human soft tissue sarcoma cell line RD and Escherichia Coli WP2. Chem Biol Interact 97:287-296.
27. Osborne MR, Wilman DEV, and Lawley PD (1995b) Alkylation of DNA by the nitrogen mustard bis(2-chloroethyl)methylamine. Chem Res Toxicol 8:316-320.
28. Palom Y, Suresh KG, Tang LQ, Paz MM, Musser SM, Rockwell S, and Tomasz M (2002) Relative toxicities of DNA cross-links and monoadducts: new insights from studies of decarbamoyl mitomycin C and mitomycin C. Chem Res Toxicol 15:1398-1406.
29. Roehm NW, Rodgers GH, Hatfield SM, and Glasebrook AL (1991) An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 142:257-265.
30. Ross WCJ (1962) Biological Alkylating Agents. Butterworths, London.
31. Ross WE, Ewig RAG, and Kohn KW (1978) Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res 38:1502-1506.
32. Tilby MJ, Johnson C, Knox R, Cordell J, Roberts JJ, and Dean CJ (1991) Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res 51:123-129.
33. Tilby MJ, Lawley PD, and Farmer PB (1990) Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products from reaction of melphalan with DGMP and GMP. Chem Biol Interact 73:183-194.
34. Tilby MJ, McCartney H, Gould KA, O'Hare CC, Hartley JA, Hall AG, Golding BT, and Lawley PD (1998) A monofunctional derivative of melphalan: preparation, DNA alkylation products and determination of the specificity of monoclonal antibodies that recognize melphalan-DNA adducts. Chem Res Toxicol 11:1162-1168.
35. Tilby MJ, Newell DR, Viner C, Selby PJ, and Dean CJ (1993) Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy. Eur J Cancer 29A:681-686.
36. Tilby MJ, Styles JM, and Dean CJ (1987) Immunological detection of DNA damage caused by melphalan using monoclonal antibodies. Cancer Res 47:1542-1546.
37. Tokuda K and Bodell WJ (1987) Cytotoxicity and sister chromatid exchanges in 9L cells treated with monofunctional and bifunctional mustards. Carcinogenesis 8:1697-1701.
38. Unsal-Kacmaz K, Makhov AM, Griffith JD, and Sancar A (2002) Preferential binding of ATR protein to UV-damaged DNA. Proc Natl Acad Sci USA 98:6673-6678.
39. Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ, Adams JM, and Strasser A (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science (Wash DC) 302:1036-1038.
40. Wieler S, Gagne JP, Vaziri H, Poirier GG, and Benchimol S (2003) Poly(ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation. J Biol Chem 278:18914-18921.